MedSigLIP Does Not Exist as a Medication
"MedSigLIP" is not a recognized medication name in the FDA-approved drug database or medical literature, and therefore has no black box warning. This appears to be either a misunderstanding, misspelling, or confusion with another medication name.
Possible Interpretations
Based on the context of your question about black box warnings, you may be asking about:
If You're Asking About Lipid-Lowering Medications
Several lipid management therapies do carry black box warnings:
Lomitapide has two black box warnings: (1) hepatotoxicity with elevated liver transaminases, and (2) hepatic steatosis that may progress to steatohepatitis and cirrhosis. It is only available through a REMS (Risk Evaluation and Mitigation Strategy) program due to these hepatic risks 1.
Most statin medications do not carry black box warnings, though they have important warnings about myopathy and rhabdomyolysis 1.
PCSK9 inhibitors (evolocumab, alirocumab) and evinacumab do not have black box warnings 1.
Understanding Black Box Warnings
Black box warnings are the FDA's strongest safety warning for marketed prescription drugs, indicating potentially serious or life-threatening adverse effects 2, 3. They are issued when:
- There is a potentially serious adverse effect that must be carefully weighed against the drug's benefit 2
- Special attention is needed for dosing, monitoring requirements, or drug interactions 2
- Post-marketing surveillance identifies significant safety concerns 2
Common pitfall: Not all serious medications have black box warnings, and the presence of a black box warning doesn't necessarily mean a drug should be avoided—it means careful patient selection and monitoring are essential 4.
Next Steps
Please verify the correct medication name you're inquiring about, as this will allow for accurate safety information to be provided.